Royalty Pharma plc: EVP, research & investments Urist Marshall sold 4,126 shares

What happened Urist Marshall, EVP, research & investments, sold 4,126 shares at $57.10 per share on Oct 5, 2026, for $235,595. The Form 4 lists the trade as an open market or private sale (code S).

Key details

• Transaction date and price: Oct 5, 2026 — sale of 4,126 shares at $57.10 per share (S).
• Shares owned after the transaction: not specified on the Form 4; remarks state the reporting person and family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,444,120 Class A ordinary shares and Class E ordinary shares of Royalty Pharma Holdings Ltd exchangeable into 1,356,528 Class A ordinary shares (Class E ordinary shares are subject to vesting conditions).
• Footnote: all reported transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on Jun 26, 2026 (F1).
• Filing date and report period: filed Oct 5, 2026; report period Oct 5, 2026.

Why it may matter The sale was executed in the market or as a private sale under a pre-established 10b5-1 plan, per the filing. The remarks show additional exchangeable interests that could convert into large numbers of Class A ordinary shares. A filing does not show why the insider traded or why the company acted.